Company / Cash & Equivalents
Jade Biosciences, Inc. Cash & Equivalents History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$33.8M
FY2024
5-year range
$4.6M / $54.2M
FY2020-FY2024
Trend
+43.7%
vs FY2023
Sector context
#192 of 208
Health Care
What the data says
Among 208 Health Care companies, Jade Biosciences, Inc. is in the bottom 8% for cash & equivalents. Improved from $22M to $34M over the past 2 years.
Based on SEC 10-K filings.
$34M in FY2024 with a 3-year CAGR of -14.6%.
Improved from $22M to $34M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -14.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 208This company $33.8M Sector average $694.3M
▼
-95.1% below sector average
Key checks
Key Insights
- 3-year CAGR of -14.6%, indicating a declining trend.
- In FY2024, cash & equivalents increased 43.7% year-over-year.
- Ranks #192 out of 208 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $33.8M | +43.7% |
| FY2023 | $23.5M | +4.9% |
| FY2022 | $22.4M | -58.7% |
| FY2021 | $54.2M | +1085.2% |
| FY2020 | $4.6M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026